Biomarker for detecting cancer
AssigneeBoard of Regents, The University of Texas System
InventorsRobert Bresalier, Nachman Mazurek, James C. Byrd
Life of this patent
Estimating the term…
Abstract
Methods for detecting colorectal cancer or precancerous conditions such as adenomatous polyps in a subject by detection of a galactose-containing 40-kDa molecule in a serum sample from the subject are provided. Methods for quantifying the amount of a galactose-containing molecule in a serum sample are also provided. The methods can further comprise assaying the sample for the quantity of at least one additional marker to confirm the detection or diagnosis of colorectal cancer using one or more additional quantitative immune-detection assays; the additional marker can be at least one of galectin-3, a peptide derived from galectin-3, carcinoembryonic antigen (CEA), and CYFRA21-1.
Claims24
A method for treating a subject having a colorectal cancer or a precancerous condition of the digestive tract comprising performing a colonoscopy or polypectomy on the subject after having been determined to have a colorectal cancer or precancerous condition of the digestive tract, said method comprising:
- (a) measuring the level of markers consisting of galectin-3 ligand, carcinoembryonic antigen (CEA), and CYFRA21-1 in a serum or plasma sample from the subject, wherein a subject with an elevated level of galectin-3 ligand, CEA and CYFRA21-1 as compared with a control level is determined to have a colorectal cancer or a precancerous condition of the digestive tract, wherein the galectin-3 ligand is the 40 kDa haptoglobin glycoform;
- and
- (b) performing a polypectomy or removing polyps during a colonoscopy on the subject determined to have a colorectal cancer or precancerous condition of the digestive tract.
Dependencies are inferred from the claim text.